Safety and parents´ acceptance of ultrasound contrast agents in children and adolescents – contrast enhanced voiding urosonography and contrast enhanced ultrasound
Medical Ultrasonography · 16.02.2022 · 24 (1) · 27
DOI: 10.11152/mu-3196 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Ultrasonography, online erschienen am 16.02.2022. Verfasst von Josefina Seelbach und 4 weiteren Autor:innen. Beteiligte Einrichtung: Section of Pediatric Radiology, Institute of Diagnostic and Interventional Radiology, University hospital Jena, Jena, Germany. josefina.seelbach@gmx.…. Hauptthemen laut MEDLINE: Contrast Media, Vesico-Ureteral Reflux. Die Arbeit wurde bisher 9-mal zitiert (Crossref).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Aims
To evaluate the safety of the contrast enhanced voiding urosonography (ceVUS) and contrast enhanced ultrasound (CEUS) in children and adolescence and to receive data about parents’ acceptance of intravesical and intravenous application of sulfur hexafluoride.Material and methods: In this prospective, single centre study conducted over a 1 year study period, parents of 56 children (f/m=32/24; mean age 3.1 years; range 3 weeks - 15.9 years) with ceVUS and of 30 children (f/m=15/15; mean age 10.5 years; range 2 months - 17.7 years) with CEUS agreed to be included. A standardized telephone survey about the acceptance of the parents during and after the procedure as well as the adverse events (AE) were conducted within three days of the examination.
Results
The parents would agree with the use of both ceVUS and CEUS as a diagnostic tool again in 96% (54/56) or 100% (30/30) of the cases, respectively and 92.9% (52/56) would prefer ceVUS to voiding cystourethrography (VCUG). In addition, 83.3% (25/30) would prefer CEUS to CT and 73.3% (22/30) would prefer CEUS to MRI. AE were reported in 3.6% after ceVUS (2/56; skin rash, mild fever) and in 3.3% after CEUS (1/30; vomiting). AE were subacute and self‑limited.
Conclusions
The vast majority of parents prefer ceVUS and CEUS to VCUG, CT or MRI because of the safety profile of the contrast agent and diagnostic accuracy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Section of Pediatric Radiology, Institute of Diagnostic and Interventional Radiology, University hospital Jena, Jena, Germany. josefina.seelbach@gmx.de.
- Section of Pediatric Radiology, Institute of Diagnostic and Interventional Radiology, University hospital Jena, Jena, Germany. paul-christian.krueger@med.uni-jena.de.
- Section of Pediatric Radiology, Institute of Diagnostic and Interventional Radiology, University hospital Jena, Jena, Germany. matthias.waginger@med.uni-jena.de.
- Section of Pediatric Radiology, Institute of Diagnostic and Interventional Radiology, Medizinische Hochschule Hannover, Hannover, Germany. renz.diane@mh-hannover.de.
- Section of Pediatric Radiology, Institute of Diagnostic and Interventional Radiology, University hospital Jena, Jena, Germany. hans-joachim.mentzel@med.uni-jena.de.
Zitieren
APA
Seelbach, J., Krüger, P. C., Waginger, M., Renz, D. M., & Mentzel, H. J. (2022). Safety and parents´ acceptance of ultrasound contrast agents in children and adolescents – contrast enhanced voiding urosonography and contrast enhanced ultrasound. Medical Ultrasonography, 24(1), 27. https://doi.org/10.11152/mu-3196
Vancouver
Seelbach J, Krüger PC, Waginger M, Renz DM, Mentzel HJ. Safety and parents´ acceptance of ultrasound contrast agents in children and adolescents – contrast enhanced voiding urosonography and contrast enhanced ultrasound. Medical Ultrasonography. 2022;24(1):27. doi:10.11152/mu-3196
BibTeX
@article{Seelbach2022,
author = {Seelbach, Josefina and Krüger, Paul C and Waginger, Matthias and Renz, Diane M and Mentzel, Hans-Joachim},
title = {Safety and parents´ acceptance of ultrasound contrast agents in children and adolescents – contrast enhanced voiding urosonography and contrast enhanced ultrasound},
journal = {Medical Ultrasonography},
year = {2022},
volume = {24},
number = {1},
pages = {27},
doi = {10.11152/mu-3196}
}
EUVIMED